David Newman, MD
Family Medicine · Batavia, NYNPI 1104824705
Payments from drug & device makers
Across 103 payments — averaging $101.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$8K
- Prodigy Surgical Distribution, Inc.$843
- Novo Nordisk$214
- Johnson & Johnson$169
- Pfizer$119
- Indivior Inc.$86
- plus $705 from 18 others
What the payments were for
- Speaking & faculty fees$8,33880%
- Travel & lodging$7627%
- Food & beverage$1,37513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 8 | $8,338 |
| Prodigy Surgical Distribution, Inc. | 3 | $843 |
| Novo Nordisk | 12 | $214 |
| Johnson & Johnson(2 entities) | 19 | $169 |
| Pfizer | 8 | $119 |
| Indivior Inc. | 6 | $86 |
| AbbVie | 5 | $84 |
| MDD US Operations, LLC | 4 | $77 |
| Boehringer Ingelheim | 5 | $77 |
| Gilead | 5 | $71 |
| Lilly USA, LLC | 4 | $62 |
| Amgen | 4 | $52 |
| Merck | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 3 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| GSK | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$6,875
How this compares
$10,475 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $54,319 |
| OzempicSemaglutide | 30 | $39,859 |
| JardianceEmpagliflozin | 18 | $23,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,575 |
| Atorvastatin Calcium | 262 | $3,348 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,188 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,798 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,154 |
| Levothyroxine Sodium | 152 | $2,001 |
| Metoprolol Succinate | 125 | $1,935 |
| Rosuvastatin Calcium | 124 | $1,683 |
| Omeprazole | 78 | $1,379 |
| Gabapentin | 52 | $1,336 |
| Lisinopril | 124 | $970 |
| Amlodipine Besylate | 118 | $925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $54,31948 claims |
| Novo NordiskOzempic | $214 | $39,85930 claims |
| Boehringer IngelheimJardiance | $77 | $23,98018 claims |
| GSKTrelegy Ellipta | $31 | $20,57527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Batavia
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.